Type 1 Diabetes Awareness Campaign - K1DS ARE HEROES - started
mehr
Storys zum Thema Medikament
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
New study from Waltham Petcare Science Institute, part of Mars Petcare, shows cannabidiol (CBD) is effective at reducing stress in dog
WALTHAM-ON-THE-WOLDS, England (ots/PRNewswire) - - Single dose of THC-free CBD reduced stress in healthy dogs - The study, conducted by the Waltham Petcare Science Institute, was published today in Frontiers in Veterinary Science. Results from a study performed by the Waltham Petcare Science Institute published ...
mehrBlood Donation Day at R-Biopharm: Employees Help Save Lives
mehrPress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Ein DokumentmehrBreakthrough - EUR 50 million investment for start-up BrainRepair UG / Pivotal trial on stem cell treatment for brain damage in newborns fully funded
mehrCO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg
Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...
mehrMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrPress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
Ein DokumentmehrGerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
Düsseldorf (ots) - At today’s Capital Markets Day, Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted ...
Ein DokumentmehrTechnische Universität München
New X-ray technology can improve Covid-19 diagnosis
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1692790 NEWS RELEASE New X-ray technology can improve Covid-19 diagnosis Patient study demonstrates benefits of dark-field X-ray technology A research team at the Technical University of Munich (TUM) has, for the first time, produced dark-field X-ray images of ...
mehrapoplex medical technologies GmbH
Algorithm-based secondary stroke prevention finds great responses
mehrTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
mehrFlu tests from R-Biopharm also detect new virus variants
mehrHearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...
mehrJanneke van der Kamp joins Grünenthal as new Chief Commercial Officer
mehrTechnische Universität München
Tumors: forecasting the risks of brain surgery
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 18198 - email: presse@tum.de - web: www.tum.de This text on the web: http://go.tum.de/619311 Pictures: http://go.tum.de/010709 - http://go.tum.de/959985 - http://go.tum.de/098359 - http://go.tum.de/754050 - http://go.tum.de/109729 Accurately predicting possible post-surgical effects on speech Tumors: forecasting the risks of brain surgery ...
mehrStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
mehrTechnische Universität München
Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid aggregates
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22779 - email: presse@tum.de - web: www.tum.de Image download: https://mediatum.ub.tum.de/652209?show_id=1691364 NEWS RELEASE Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid ...
mehrVectorBuilder Raised $57 Million for Gene Delivery R&D
mehrVectorBuilder raised $57 million for gene delivery R&D
mehrMetrics in Balance und DNA Talks schließen sich zusammen und betreten den europäischen Lifestyle-Markt unter einem neuen Namen: LifeTalks
mehrKlinik für Prostata-Therapie Heidelberg
Focal therapy for prostate cancer: Reliable diagnosis leads to gentle treatment
mehrType 1 diabetes: New findings on the development of the autoimmune disease in children
mehrTechnische Universität München
Improved monitoring of silicone implants
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/aktuelles/alle-meldungen/pressemitteilungen/details/verbessertes-monitoring-von-silikonimplantaten Pictures: https://mediatum.ub.tum.de/1687409 NEWS RELEASE Improved monitoring of silicone implants New algorithm for clinical MRI scanners makes breast ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...
mehrEfficient AI technology for MRI data analysis
mehr- 2
Vitamin K prevents cell death: a new function for a long-known molecule
mehr Technische Universität München
New center for digital medicine and health
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37491 Images: https://mediatum.ub.tum.de/1663381 NEWS RELEASE Interdisciplinary research for the digital medicine of the future Federal and state governments approve funding for digital medicine and health center ...
mehrLeukocare announces new management structure to support global set-up and accelerate growth
Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board ...
mehr
Vorherige12345678Nächste